The use of kinase inhibitors targeting the BCR pathway (ibrutinib and idelalisib) [20, 21] and the anti-apoptotic protein BCL2 (venetoclax) in the treatment of CLL has yielded great results, especially in patients with TP53 aberrations [22-24]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.